Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients
Status:
Active, not recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This is a single center non-blinded randomized non-comparative phase II trial. The first
stage of the trial consists of five arms ( with induction treatment followed by nivolumab, 1
with no induction treatment before nivolumab).
For the second stage, the number of arms will be reduced based on the results obtained in the
first stage.